AnaptysBio (ANAB)
(Delayed Data from NSDQ)
$38.48 USD
+0.95 (2.53%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $38.50 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Income Statements
Fiscal Year end for AnaptysBio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 17 | 10 | 63 | 75 | 8 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 17 | 10 | 63 | 75 | 8 |
Selling & Adminstrative & Depr. & Amort Expenses | 182 | 125 | 120 | 99 | 115 |
Income After Depreciation & Amortization | -164 | -115 | -57 | -24 | -107 |
Non-Operating Income | 1 | -14 | -1 | 4 | 11 |
Interest Expense | 0 | 0 | 0 | 0 | 1 |
Pretax Income | -164 | -129 | -58 | -20 | -97 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -164 | -129 | -58 | -20 | -97 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -164 | -129 | -58 | -20 | -97 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -173 | -115 | -54 | -23 | -107 |
Depreciation & Amortization (Cash Flow) | -8 | 0 | 3 | 1 | 1 |
Income After Depreciation & Amortization | -164 | -115 | -57 | -24 | -107 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 26.92 | 28.17 | 27.43 | 27.30 | 27.06 |
Diluted EPS Before Non-Recurring Items | -6.08 | -4.57 | -2.06 | -0.73 | -3.60 |
Diluted Net EPS (GAAP) | -6.08 | -4.57 | -2.11 | -0.73 | -3.60 |
Fiscal Year end for AnaptysBio, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 10.97 | 7.18 | 9.01 | 3.32 | 3.46 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 10.97 | 7.18 | 9.01 | 3.32 | 3.46 |
SG&A, R&D, and Dept/Amort Expenses | 51.30 | 49.38 | 43.81 | 41.05 | 43.60 |
Income After SG&A, R&D, and Dept/Amort Expenses | -40.33 | -42.20 | -34.80 | -37.73 | -40.14 |
Non-Operating Income | -6.33 | -1.74 | -0.08 | 0.42 | 0.30 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -46.65 | -43.94 | -42.22 | -37.31 | -39.85 |
Income Taxes | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -46.66 | -43.94 | -42.21 | -37.31 | -39.85 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -46.66 | -43.94 | -42.21 | -37.31 | -39.85 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 27.36 | 26.80 | 26.59 | 26.55 | 26.63 |
Diluted EPS Before Non-Recurring Items | -1.71 | -1.64 | -1.59 | -1.41 | -1.50 |
Diluted Net EPS (GAAP) | -1.71 | -1.64 | -1.59 | -1.41 | -1.50 |